Cytoreductive Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma in the Targeted Therapy Era.

Autor:	Uprety D; Department of Medical Oncology, Gundersen Health System, La Crosse, WI, U.S.A. upretydipesh@gmail.com., Bista A; Department of Medical Oncology, Gundersen Health System, La Crosse, WI, U.S.A., Smith AL; Division of Medical Research, Gundersen Lutheran Medical Foundation, La Crosse, WI, U.S.A., Vallatharasu Y; Department of Medical Oncology, Gundersen Health System, La Crosse, WI, U.S.A., Marinier DE; Department of Medical Oncology, Gundersen Health System, La Crosse, WI, U.S.A.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2018 May; Vol. 38 (5), pp. 3013-3018.
DOI:	10.21873/anticanres.12555
Abstrakt:	Background/aim: The role of cytoreductive nephrectomy (CN) for metastatic renal cell cancer (mRCC) is not clearly understood after the approval of targeted therapies, particularly in the elderly population. The aim of this study was to compare survivals between patients who did and did not receive CN. Patients and Methods: The SEER-18 database was utilized in order to identify elderly patients with mRCC to compare overall survival (OS) and cancer-specific survival (CSS) between patients who did or did not receive CN between February 2006 and 2012. Kaplan-Meier curve and log rank test were used to compare OS and CSS between these two arms. Cox proportional hazard model was used for multivariate analysis and statistical significance was defined as p≤0.05. Results: There was a significant survival benefit for those who received CN compared to those who did not receive CN (median OS: 18 months vs. 4 months, p<0.001; median CSS: 21 months vs. 5 months, p<0.001). Conclusion: CN offered significant survival benefit, even in elderly patients with metastatic renal cell cancer. (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu